Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1675
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17872225 | METHODS FOR TREATING CHRONIC SPONTANEOUS URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 17849075 | METHODS AND COMPOSITIONS FOR INHIBITING P97 | Final Rejection | California Institute of Technology |
| 17769722 | NEONATAL FC RECEPTOR BINDING AFFIMERS | Final Rejection | LG CHEM, LTD. |
| 19237968 | DUAL CSF1-IL-10 CYTOKINE | Final Rejection | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA |
| 17637682 | METHODS AND COMPOSITIONS FOR TREATING PAX6-DEFICIENCY RELATED DISEASE | Final Rejection | RAMOT AT TEL-AVIV UNIVERSITY LTD |
| 17920503 | STRUCTURALLY-STABILIZED AND HDMX-SELECTIVE P53 PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17622504 | METHODS AND MATERIALS FOR TARGETED EXPANSION OF REGULATORY T CELLS | Non-Final OA | The Johns Hopkins University |
| 17537816 | CYTOKINE COCKTAILS FOR SELECTIVE EXPANSION OF T CELL SUBSETS | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17774298 | HLA RESTRICTED HORMAD1 T CELL RECEPTORS AND USES THEREOF | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17764104 | IMMUNOGENIC EGFR PEPTIDE COMPOSITIONS AND THEIR USE IN THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 18302630 | METHOD OF CREATING HUMAN PLURIPOTENT STEM CELL DERIVED BRAIN PERICYTE-LIKE CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17799503 | NOVEL T CELL RECEPTORS (TCRS) THAT REACT TO NEOANTIGENS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17769642 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | Non-Final OA | Yale University |
| 17906467 | MULTIVALENT CHEMOKINE RECEPTOR BINDING COMPLEXES | Non-Final OA | CITY OF HOPE |
| 17914261 | MASKED IL12 FUSION PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Zymeworks BC Inc. |
| 17926673 | IMPROVED GRANZYME B VARIANT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17692755 | IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS | Non-Final OA | Xencor, Inc. |
| 17420556 | mRNA Vaccine | Final Rejection | eTheRNA Immunotherapies NV |
| 17599921 | Fc-MODIFIED BIOLOGICALS FOR LOCAL DELIVERY TO COMPARTMENT, IN PARTICULAR TO THE CNS | Non-Final OA | Universität Zürich |
| 17763973 | STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR | Final Rejection | LONZA SALES AG |
| 18002613 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Non-Final OA | Inhibrx Biosciences, Inc. |
| 17777088 | INTERLEUKIN 15 FUSION PROTEINS AND PRODRUGS, AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | IMMUNE TARGETING INC. |
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Cue Biopharma, Inc. |
| 17930319 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Non-Final OA | Ambrx, Inc. |
| 18046670 | ANTIGEN POOL | Non-Final OA | Enara Bio Limited |
| 18046675 | FUSION PROTEINS OF CTL ANTIGENS FOR TREATING MELANOMA | Non-Final OA | Enara Bio Limited |
| 17909658 | COMBINED USE OF CTB006 AND PONATINIB | Non-Final OA | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | Final Rejection | UVic Industry Partnerships Inc. |
| 17210454 | COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE AND BACTERIAL INFECTION | Final Rejection | Prince Biotech, LLC |
| 17634890 | IL-2 FUSION PROTEINS THAT PREFERENTIALLY BIND IL-2RALPHA | Final Rejection | ASKGENE PHARMA, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy